AVDL and ALKS Related Headlines
Go Back- Alkermes completes $775 million acquisition of Avadel Pharmaceuticals
- Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market
- Announcement relating to despatch of Rule 15 proposal
- Alkermes increases Avadel acquisition offer to $22.50 per share
- Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc
- Avadel board deems Lundbeck's $2.4 billion bid superior to Alkermes deal
- Avadel Board of Directors Declares Lundbeck Proposal a “Company Superior Proposal”
- Alkermes responds to competing offer for Avadel from Lundbeck
- Avadel receives $23 per share takeover bid from Lundbeck
- Avadel Receives Unsolicited Proposal from Lundbeck
- RBC Capital on Jazz Pharmaceuticals (JAZZ): 'we would be buyers on the potential upcoming positive ph.III zanidatimab data in GEA'
- Alkermes to acquire Avadel for up to $2.1 billion in cash deal
- Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc
AVDL and ALKS Related Press Releases
Go Back- Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market
- Announcement relating to despatch of Rule 15 proposal
- Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc
- Avadel Board of Directors Declares Lundbeck Proposal a “Company Superior Proposal”
- Avadel Receives Unsolicited Proposal from Lundbeck
- Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc
